Immune response to polyglycolic acid implants.
Cytological analysis of material aspirated from the effusion which occasionally develops around a polyglycolic acid (PGA) osteosynthesis implant showed a predominance of inflammatory monocytes and in particular lymphocytes. In order to discover whether PGA implants are immunologically inert, density gradient-isolated peripheral blood mononuclear cells were cultured in 0.2 ml of 10% delta FCS-RPMI 1640 culture medium supplemented with 10 mg PGA. Phytohaemagglutinin (PHA) lectin, a purified protein derivate of tuberculin (PPD) antigen and culture medium alone were used as positive and negative controls. We studied lymphocyte activation kinetics on days 0, 1, 3 and 5. Major histocompatibility complex locus II antigen (MHC locus II antigen) and interleukin-2 receptor (IL-2R) expression were analysed using the avidin-biotin-peroxidase complex (ABC) method and lymphocyte DNA synthesis by using 3H-thymidine incorporation and beta-scintillation counting. Especially on culture days 0 and 1, lymphocytes and monocytes were seen by light microscopy to be attached to PGA particles. However, our results show no PGA-induced lymphocyte DNA synthesis, but PGA-induced MHC locus II antigen and IL-2R activation marker expression was seen, greater than in negative controls, but less than that seen in PPD antigen driven lymphocyte response. This suggests that PGA is an immunologically inert implant material, but it does seem to induce inflammatory mononuclear cell migration and adhesion, leading to a slight non-specific lymphocyte activation. This activation is lower than that seen in mitogen and antigen-driven lymphocyte responses.
Santavirta
S
S
Helsinki University, Central Hospital, Finland.
Konttinen
Y T
YT
Saito
T
T
Grönblad
M
M
Partio
E
E
Kemppinen
P
P
Rokkanen
P
P
D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis; D005593:Fracture Fixation, Internal; D000949:Histocompatibility Antigens Class II / Q000302:isolation & purification*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects*; D008213:Lymphocyte Activation / Q000187:drug effects; D011100:Polyglycolic Acid / Q000494:pharmacology*; D019736:Prostheses and Implants; D015375:Receptors, Interleukin-2 / Q000302:isolation & purification
D000949:Histocompatibility Antigens Class II; D015375:Receptors, Interleukin-2; D011100:Polyglycolic Acid; D004247:DNA